drugset / Trial / NCT02875340

A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02875340

Phase 2 Completed 8 enrolled ValiSeek Limited
NaSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.

Timeline

Start
2016-10
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 2 mg Oral
Subject Risperidone Other / unclassified 10 mg Oral